First Trust Advisors’s Enliven Therapeutics ELVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.23M Buy
+92,195
New +$5.02M ﹤0.01% 1682

Other funds holding ELVN

First Trust Advisors's ELVN Position: Q3 2026 in Review

First Trust Advisors opened a new position in Enliven Therapeutics (ELVN) in Q3 2026: 92,195 shares worth $4.23M. The stake represents ﹤0.01% of the portfolio and ranks #1682 among its holdings.

216 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • First Trust Advisors held 92,195 shares of Enliven Therapeutics worth $4.23M as of Q3 2026.
  • Enliven Therapeutics was a new First Trust Advisors position in Q3 2026.
  • Enliven Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q3 2026, its #1682 holding.
  • 216 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on First Trust Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.